In recent years, the results of pharmacologic therapy for preventing VAs are disappointing. Therapy limitations are due to variable efficacy, pro-arrhythmic effects, patient compliance, and adverse effects from long-term therapy. in patients with ICDs, adjuvant suppressive therapy as amiodarone and sotalol have been shown to reduce the rate of recurrent VT when compared with beta-blockers or placebo. Pharmacologic therapy (amiodarone or sotalol) with or without adjunctive catheter ablation are recommended by the current guidelines to prevent VT/VF recurrence and reducing ICD shocks
Ventricular tachycardia future or investigational therapies
Pulseless ventricular tachycardia primary prevention
Ventricular tachycardia primary prevention
Atrial fibrillation primary prevention
Atrial fibrillation secondary prevention
Cardiomegaly future or investigational therapies
Atrial fibrillation urgent treatment
Ventricular tachycardia secondary prevention